Pacific Biosciences of California (PACB) Competitors

Pacific Biosciences of California (NASDAQ:PACB) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Is PACB or HBIO more profitable?

Harvard Bioscience has a net margin of -14.57% compared to Pacific Biosciences of California's net margin of -227.69%. Harvard Bioscience's return on equity of -4.64% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-227.69%	-42.71%	-15.38%
Harvard Bioscience	-14.57%	-4.64%	-2.40%

Do analysts recommend PACB or HBIO?

Pacific Biosciences of California currently has a consensus price target of $2.95, suggesting a potential upside of 59.71%. Given Pacific Biosciences of California's stronger consensus rating and higher probable upside, equities analysts plainly believe Pacific Biosciences of California is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Harvard Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Do institutionals & insiders have more ownership in PACB or HBIO?

80.9% of Harvard Bioscience shares are held by institutional investors. 2.4% of Pacific Biosciences of California shares are held by insiders. Comparatively, 9.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Which has higher valuation & earnings, PACB or HBIO?

Harvard Bioscience has lower revenue, but higher earnings than Pacific Biosciences of California. Harvard Bioscience is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$173.15M	2.93	-$306.73M	-$1.46	-1.27
Harvard Bioscience	$112.25M	0.81	-$3.41M	-$0.33	-6.33

Does the media favor PACB or HBIO?

In the previous week, Pacific Biosciences of California had 5 more articles in the media than Harvard Bioscience. MarketBeat recorded 5 mentions for Pacific Biosciences of California and 0 mentions for Harvard Bioscience. Pacific Biosciences of California's average media sentiment score of 0.93 beat Harvard Bioscience's score of -1.00 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Overall Sentiment
Pacific Biosciences of California	Positive
Harvard Bioscience	Negative

Does the MarketBeat Community favor PACB or HBIO?

Pacific Biosciences of California received 82 more outperform votes than Harvard Bioscience when rated by MarketBeat users. However, 72.02% of users gave Harvard Bioscience an outperform vote while only 66.86% of users gave Pacific Biosciences of California an outperform vote.

Company	Underperform	Outperform
Pacific Biosciences of California	Outperform Votes 450 66.86%	Underperform Votes 223 33.14%
Harvard Bioscience	Outperform Votes 368 72.02%	Underperform Votes 143 27.98%

Which has more volatility and risk, PACB or HBIO?

Pacific Biosciences of California has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Summary

Pacific Biosciences of California beats Harvard Bioscience on 10 of the 18 factors compared between the two stocks.